To elucidate the role of the branched structure of sugar chains of human erythropoietin (EPO) in the expression of in vivo activity, the pharmacokinetic profile of a l e s s active recombinant human EPO sample (EPO-bi) enriched with biantennary sugar chains was compared with that of a highly active control EPO sample enriched with tetraantennary sugar chains. After an intravenous injection in rats, lz5I-EPObi disappeared from the plasma with 3.2 times greater total body clearance (Cl,J than control '%EPO. Whole-body autoradiography after 20 minutes of administration indicated that the overall distribution of radioactivity is similar, but '=I-EPO-bi showed a higher level of radioactivity in the kidneys than control '%EPO. Quantitative determination of radioactivity in the tissues also indicated that radioactivity of '%EPO-bi in the kidneys was two times higher than that RYTHROPOIETIN (EPO) is a glycoprotein hormone that stimulates proliferation and differentiation of erythroid progenitor cells.' EPO has three N-linked and one 0-linked sugar chains, and the sugar content is approximately 40% of its molecular weight of 30.4 kD.',3 The recombinant DNA technique has enabled us to produce a sufficient amount of EPO? To date, its sugar chain structures have been well in~estigated.~.' From the analysis of EPO modified by enzymatic and chemical treatment9"' or produced by the recombinant DNA t e~h n i q u e ,~~-'~ it has been shown that the N-linked sugar chains of EPO play important roles in biosynthesis, secretion, and expression of biologic activity. In many cases, modification of the sugar portion of EPO resulted in a decrease or a complete loss of in vivo biologic activity, whereas it maintained or increased in vitro activity. A typical example is that the removal of terminal sialic acid residues from the sugar chains of EPO causes complete loss of in vivo biologic activity but increases in vitro biologic activity."," The loss of in vivo biologic activity of asialo-EPO could be explained by a rapid removal from the systemic circulation,'9~'o which resulted from hepatic uptake mediated by a galactose-binding protein'' and degradation in the lysosome.
RYTHROPOIETIN (EPO) is a glycoprotein hormone
that stimulates proliferation and differentiation of erythroid progenitor cells.' EPO has three N-linked and one 0-linked sugar chains, and the sugar content is approximately 40% of its molecular weight of 30.4 kD.', 3 The recombinant DNA technique has enabled us to produce a sufficient amount of EPO? To date, its sugar chain structures have been well in~estigated.~.' From the analysis of EPO modified by enzymatic and chemical treatment9"' or produced by the recombinant DNA t e~h n i q u e ,~~-'~ it has been shown that the N-linked sugar chains of EPO play important roles in biosynthesis, secretion, and expression of biologic activity. In many cases, modification of the sugar portion of EPO resulted in a decrease or a complete loss of in vivo biologic activity, whereas it maintained or increased in vitro activity. A typical example is that the removal of terminal sialic acid residues from the sugar chains of EPO causes complete loss of in vivo biologic activity but increases in vitro biologic activity."," The loss of in vivo biologic activity of asialo-EPO could be explained by a rapid removal from the systemic circulation,'9~'o which resulted from hepatic uptake mediated by a galactose-binding protein'' and degradation in the lysosome.
Recombinant human EPO produced by Chinese hamster ovary cells is usually highly active, and contains N-linked sugar chains mostly composed of tetraantennary structure^.^.^ However, in our previous studyi4 we found a unique EPO sample (EPO-bi) that has less in vivo biologic activity and contains higher amounts of biantennary N-linked sugar chains than the usual EPO sample. Analysis of several EPO samples with different in vivo activities showed that there is a positive correlation between the ratio of tetraantennary to biantennary sugar chains included in EPO and its biologic activity in vivo. Interestingly, the degree of galactose exposure did not correlate with the in vivo activity among the EPO samples used. Considering that EPO-bi shows higher in vitro activity than the usual EPO sample, it is suggested that the lower in vivo activity of EPO-bi results from its less efficient delivery to target cells in the bone marrow. To find a clue to understanding the mechanism by which EPO expresses in vivo biologic activity depending on the anten- nary structure of N-linked sugar chains included in this hormone, we examined the pharmacokinetics of EPO-bi using the usual highly active EPO sample as a control in this study.
MATERIALS AND METHODS
Preparation and iodination of EPO samples. Two EPO samples used in this study, EPO-bi and control EPO, were produced by recombinant Chinese hamster ovary cells and purified as previously de~cribed.~.'~ The in vivo biologic activities of EPO-bi and control EPO determined by the exhypoxic, polycythemic mice bioassay" were 53 and 240 IU/pg protein, respectively. In vitro activity of EPO-bi assayed using cultured rat bone marrow cells" was 1.8-fold higher than that of control EPO. These EPO samples were iodinated by the chloramine-T methodz3 using carrier-free Iz5I (Amersham, Buckinghamshire, UK) and purified by gel filtration using a PD-10 column (Pharmacia, Uppsala, Sweden). Human serum albumin was added to the labeled samples at a concentration of 0.25%. Their high purity was confirmed by gel-filtration chromatography (>96%) and by the immunoprecipitation method (>99%). These iodinated samples retained biologic activities in vivo and in vitro.
Animals and administration. Male Sprague-Dawley rats aged 5 to 6 weeks were purchased from SLC (Shizuoka, Japan). The animals were used for study at 7 to 8 weeks of age and weighing 220 to 329 g. For investigation of renal handling of EPO samples, rats were anesthetized with sodium pentobarbital 50 mgkg administered intraperitoneally to permit implantation of catheters and to perform nephrectomy. Unilateral and bilateral nephrectomies were performed by renal arteriovenous ligation, and a polyethylene catheter (PE-50) was inserted into the femoral artery. The catheter was filled with heparin (50 U/mL) in saline throughout the experiment. The shamoperated group was treated in the same way without nephrectomy.
The labeled EPO samples were diluted with 20 mmol/L sohum citrate buffer, pH 7.0, containing 100 mmol/L sodium chloride and 0.25% human serum albumin to prepare a dosing solution at a final concentration of 0.5 pg (306 to 581 kBq)/mL. Rats were given an intravenous bolus injection of dosing solution (1 mLkg) via tail vein. Plasma clearance. Each group of five rats received an intravenous injection of labeled EPO samples at a dose of 0.5 pgkg. At selected time intervals, blood was withdrawn from the tail veins and collected into heparinized test tubes. After centrifugation at 2,000 X g for 5 minutes, aliquots (20 to 50 pL) of plasma were taken for determination of total, trichloroacetic acid (TCA)-insoluble, and immunoreactive radioactivities. For investigation of renal handling of EPO samples, blood was withdrawn from the femoral artery via the catheter, and immunoreactive radioactivity in the plasma was measured. TCA-insoluble radioactivity in the plasma was measured after addition of 1 mL ice-cold 10% TCA, centrifugation at 1,000 X g for 10 minutes, and washing of the precipitate with 10% TCA. Immunoreactive radioactivity was also measured according to the immunoprecipitation method. Briefly, 0.1 mL rabbit antiserum against recombinant human EPO diluted 1:2,000 in phosphate-buffered saline containing 1% bovine serum albumin and 0.05% sodium azide was added to the aliquots. After incubation overnight at 4"C, 0.5 mL of a solution of Amerlex-M (donkey antirabbit IgG; Amersham) was added to the mixtures and incubated for 1 hour at room temperature. The precipitated fraction was obtained by centrifugation at 1, OOO X g for 10 minutes, and its radioactivity was measured. The contents of labeled materials were estimated by their specific ra&oactivity, with correction for counting efficiency and attenuation, and expressed as nanogram equivalents of protein.
Tissue distribution. Each group of three rats were given an intravenous injection of labeled EPO samples (0.5 pgkg). In the competition experiments, each group was also given an intravenous injection of labeled EPO-bi (0.05 pgkg) with or without 5-, 25-, and 125-fold larger amounts of nonlabeled EPO-bi or control EPO. At selected times, organs and tissues to be. assayed were removed from rats killed by exsanguination from the abdominal aorta under ether anesthesia, excised, and washed with saline. Blood samples were collected into heparinized tubes and centrifuged at 1,000 X g for 15 minutes to obtain the plasma. The femur freed from muscle was cut off to collect the bone marrow. The liver, spleen, and kidneys were weighed and homogenized in 4 v01 saline using a Polytron homogenizer (Kinematica, Littau-Luzern, Switzerland). Aliquots of blood, plasma, tissue homogenates, and other tissue samples were weighed, and their total radioactivities were measured. TCA-insoluble radioactivities in plasma, liver, spleen, and kidneys were also measured.
For whole-body autoradiography, animals were killed by ether inhalation at 20 minutes after an intravenous injection of labeled EPO samples and then frozen in dry ice-hexane and embedded in 4% carboxymethyl cellulose. Frozen whole-body sections 35 pm thick were prepared using a cryomicrotome (450MP PMV, Stockholm, Sweden). After freeze-drying in cryostats, the sections were placed in contact with x-ray film (MARG ' H type; Konica, Tokyo, Japan) for 3 weeks, and the film was developed to obtain the autoradiogram.
Excretion into urine. The animals were placed into glass metabolic cages (Metabolica, Sugiyamagen-Iriki, Tokyo, Japan) after intravenous injection of labeled EPO samples. Urine was collected over 0 to 6, 6 to 12, and 12 to 24 hours, and thereafter at intervals of 24 hours for 72 hours. The samples were collected in bottles containing 1 mL 1 % sodium azide and placed in a cooling bath kept at 4°C. Aliquots (200 pL) of urine were taken to measure total and immunoreactive radioactivities.
Pharmacokinetic parameters and statistical analysis. The plasma clearance data of immunoreactive radioactivity obtained for each animal were fitted to the following equation for a two-compartment model by nonlinear regression analysis with the NONLIN84 program" using a VAX8350 computer (Digital Equipment Corp, Massachusetts): C, = Ae-"' + Be-O', where C, represents the concentration in serum at time t, and A, a, B, and p are paired constants of compartments 1 and 2, respectively. The constants A and B are the y (time 0)-intercepts, and a and p are the slopes obtained from the first (a) and second (p) phases of the plot of log plasma EPO concentration versus time, respectively. According to standard techn i q u e~,~~ the computer-estimated constants a, p, A, and B were used for calculation of the following kinetic parameters: the half-lives in the first and second phases (t,,a and tl,& which are equal to -0.6931~ and -0.693/p, respectively), the volume of distribution of the central compartment (V&), and the steady-state volume of distribution (Vd,,), which is the total volume of central and peripheral compartments. The area under the concentration versus time curve (AUC) was calculated by the trapezoidal method and extrapolated to infinity. Total body clearance (CItoJ was calculated as the dose divided by AUC. Volume and clearance terms were normalized to the body weight of each rat and expressed as milliliters per kilogram and milliliters per hour per kilogram, respectively. Statistical significance was analyzed by the F test and Student's t-test for comparison of EPO-bi versus control EPO, and by one-way analysis of variance followed by Tukey's multiple range test for group comparisons.
RESULTS

Plasma clearance.
To understand the expression of in vivo biologic activity of EPO depending on the antennary structure of N-linked sugar chains, the metabolic behavior of less active EPO-bi, which has been shown to be enriched with biantennary sugar chains,I4 was examined as compared with highly active control EPO enriched with tetraantennary sugar chains. Carbohydrate structures of these two EPO samples are shown in Fig 1 . These samples were radioiodinated and given to rats by single intravenous injections, and their concentrations in plasma were determined at various time intervals (Fig 2) . Both control L251-EP0 and '"I-EPO-bi disappeared in a biphasic manner. Any measurement of total, TCA-insoluble, and immunoreactive radioactivities indicated that lZ51-EPO-bi disappeared from the circulation more rapidly than control '"I-EPO. Plasma concentrations of immunoreactive radioactivity of control EPO accounted for 95%, 89%, 87%, 76%, and 63% of the levels of total radioactivity after 20 minutes and 2, 4, 8, and 12 hours of injection, respectively. The corresponding values for EPO-bi were 95%, 70%, 54%, 35%, and 24%. These results suggest that control Iz5I-EPO is more resistant to degradation than EPObi. Pharmacokinetic parameters estimated from the plasma concentration data of immunoreactive radioactivity are summarized in Table 1 . The statistically significant differences are that EPO-bi shows a slightly shorter half-life in the elimination phase (tl,$) and approximately a two-fold larger Vd,, as compared with control EPO, and that C&,, of EPO-b1 was 3.2 times greater than that of control EPO. When nonlabeled EPO samples were given and their plasma disappearance was measured by radioimmunoassay,26 similar differences were also observed between EPO-bi and control EPO (data not shown). Tissue distribution. Tissue distributions of radioiodinated EPO-bi and control EPO at 20 minutes after intravenous injections were examined by whole-body autoradiography (Fig 3) . In rats injected with control "'I-EPO, the high level of radioactivity was detected in bone marrow, blood, kidneys, spleen, and liver. Levels of radioactivity in other organs were low. The overall distribution profile of '251-EPO- Significantly different from control '251-EP0 ( P < .01).
Each value represents the mean 5 SD of 5 rats.
bi was similar to that of control IZ5I-EPO, except that EPObi accumulated in the kidneys, especially in the renal cortex, more efficiently than control EPO. Tissue distribution was also examined by measuring radioactivity in various tissues, and the results are summarized in Table 2 . At 20 minutes of injection of Iz5I-EPO, the plasma level of radioactivity was 8.90 ng equivalents of EPO/mL, and the same level of radioactivity was detected in bone marrow ( Table 2) . Levels of radioactivity in the spleen and the kidneys were approximately 20% to 30% of those in the plasma, and levels in the liver were less than 7%. Other organs such as the submaxillary gland, stomach, pancreas, skeletal muscle, prostate, testis, epididymis, thymus, lymph nodes, and small intestine contained lesser amounts of radioactivity, which were not greater than 4% of the radioactivity in plasma (data not shown). Radioactivity in most tissues decreased in parallel with the decrease in the plasma level over 4 hours after injection. On the other hand, distribution of Iz5I-EPO-bi differed from that of control 12SI-EP0 in two respects. First, levels of "'I-EPO-bi in bone marrow were lower than those of control IZ5I-EPO, as in the case of the plasma level. This difference became more evident at 4 hours after injection than earlier. Second, radioactivity in the kidneys after 20 minutes of injection of '251-EPO-bi was approximately two times higher than that of control "'I-EPO. This To determine the mode of tissue distribution, the effect of simultaneous injection of excess amounts of nonlabeled EPO samples on the distribution profile of labeled EPO-bi was then examined. At 20 minutes after injection of a trace amount of '"I-EPO-bi (0.05 & k g ) , the highest concentration of radioactivity was observed in bone marrow, and was reduced by simultaneous injection of fivefold to 125-fold larger amounts of nonlabeled EPO-bi (Fig 4A) and control phy. Fig 4B) depending on their dose levels. There was also a similar reduction in the spleen. Replacement ability was almost the same between EPO-bi and control EPO. On the other hand, there was little effect of simultaneous injection of nonlabeled EPO samples on levels of labeled EPObi in kidneys, liver, and plasma. Thus, distribution to bone marrow and spleen seems to occur in a receptor-mediated manner, but distribution to kidneys or liver does not.
EPO (
Excretion into urine.
In both cases of '*'I-EPO-bi and control '2sI-EP0, most of the radioactivity injected was fi- nally recovered from the urine (Fig 5) . However, excretion of radioactivity from rats injected with '251-EPO-bi was faster than from rats injected with control "'I-EPO. Radioactive materials in the urine mostly occurred in nonimmunoreactive forms in both cases; the immunoreactive form obtained from control L251-EP0 was 2.9% of the dose, and that from "'I-EPO-bi was not greater than 0.3%. Low recovery of the intact form was also observed by gel-permeation chromatography (data not shown).
Renal handling of EPO-bi. From the results described earlier, it is likely that EPO-bi is cleared from the systemic circulation by renal handling. To confirm this assumption, the effect of nephrectomy on plasma clearance was examined (Fig 6) . As compared with sham-operated rats, unilaterally and bilaterally nephrectomized rats showed a slightly and a dramatically slower disappearance of Iz5I-EPO-bi from the circulation, respectively. Plasma disappearance curves of EPO-bi and control EPO were similar in bilaterally nephrectomized rats, unlike those in unoperated rats. Statistical analysis (Table 3) indicated that CI,, of 1251-EPO-bi was decreased by 20% (34.5 ? 2.7 mL/h/kg) and 60% (17.4 ? 1.3 mL/h/kg) after unilateral and bilateral nephrectomy, respectively, as compared with that in sham-operated rats (42.5 ? 3.7 mL/h/kg). Vd,, of '251-EPO-bi was also reduced to 76% and 64% of levels in sham-operated rats by unilateral and bilateral nephrectomy, respectively. Parameters in sham-operated rats were similar to those in unoperated rats ( Table  1) . On the other hand, CI,,, (13.9 ? 0.6 mLhkg) and Vd,, (64.2 ? 9.5 mwkg) of control EPO in bilaterally nephrectomized rats were similar to those in unoperated rats (Table  1) . Thus, the significant difference in CI,, and Vd,, between "'I-EPO and Iz5I-EPO-bi observed before the operation (Table l) was not observed after bilateral nephrectomy.
DISCUSSION
In this study, the metabolic basis of our previous observationI4 that an increased branching of N-linked sugar chains in EPO positively correlates with expression of its in vivo activity was examined. Comparison of phamacokinetic profiles between EPO-bi and control EPO, which differ in that EPO-bi is enriched with biantennary sugar chains and is five times less active than control EPO enriched with tetraantennary sugar chains, provided some interesting evidence.
Plasma disappearance curves of radioiodinated EPO samples after single intravenous administrations showed that EPO-bi is more rapidly cleared from the systemic circulation than control EPO. In terms of CI,,,, EPO-bi was cleared 3.2 times faster than control EPO. Vd,, of EPO-bi was approxi- 
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For mately two times larger than that of the control, suggesting that some tissues may contribute to the faster removal of EPO-bi from the systemic circulation. Subsequent analysis of tissue distribution by whole-body autoradiography at 20 minutes after injection indicated that EPO-bi is more rapidly distributed to the kidneys. Quantitative determination of radioactivity in each tissue also confirmed the rapid distribution of EPO-bi to the kidneys. Thus, renal handling is suggested to contribute to the rapid clearance of EPO-bi from the circulation. This assumption is clearly supported by the experimental nephrectomy, in which plasma clearance of EPO-bi showed a significant decrease while that of control EPO was hardly affected. There was also the reduction of Vd,, of EPO-bi to 76% and 64% after unilateral and bilateral nephrectomy. In contrast, CI,,, and Vd,, of control EPO did not significantly change after nephrectomy. Consequently. the significant difference in CI,,, and Vd,, observed between EPO-bi and control EPO before the operation vanished after bilateral nephrectomy.
The nonrenal metabolism of control EPO accords with the observations that nephrectomy does not affect clearance of urinary human EPO in rats" and sheep,28 but somehow differs from others in that clearance of urinary human EPO in ratsz9 or of recombinant human EPO in dogs'" depends on the kidney to a small extent. The nonrenal metabolism of EPO has also been shown in humans." Since different s a mples and animals were used by these groups, this minor discrepancy cannot be explained. However, these reports coincide in that EPO is largely metabolized through nonrenal mechanisms such as receptor-mediated endocytosis followed by lysosomal digestion by erythroid cells."z" Therefore, it MlSAlZU ET AL is notable that EPO-bi, and not control EPO, used in our study is cleared largely depending on the kidneys.
How do the kidneys contribute to the rapid clearance of EPO-bi from the circulation? As shown by competition experiments (Fig 4) , distribution of labeled EPO-bi to the kidneys was not significantly altered by simultaneous administration of excess amounts of nonlabeled EPO samples, whereas distribution to bone marrow or spleen was greatly affected. Thus, it is not likely that some specific receptor(s) mediates the transfer of EPO-bi to the kidneys, but it is considered that EPO-bi may be cleared via a nonspecific mechanism such as glomerular filtration. Actually, EPO-bi was excreted into the urine more rapidly than control EPO. Less than 0.3% of the dose of EPO-bi and 3% of control EPO were recovered from the urine in an immunoreactive form, respectively. This slight difference may be due to the different degradation, possibly mediated by proteinases in renal tubular cells.
Although the concentrations of EPO-bi distributed to the tissues, except for the kidneys, were similar to or less than those of control EPO (Table 2) , the tissue/plasma concentration ratios of EPO-bi were higher than those of control EPO. Therefore, it is possible to consider that EPO-bi either crosses capillaries more easily or is retained more avidly in the tissues. If this possibility is true, EPO-bi would distribute more efficiently to the tissues than control EPO on the condition that plasma concentrations of both EPO samples are the For personal use only. on October 3, 2017. by guest www.bloodjournal.org From same. However, the plasma concentration of EPO-bi is greatly affected by renal metabolism, as discussed earlier, and therefore results in its lower tissue distribution. It is also noteworthy that the distribution of radioiodinated EPO-bi to the liver was not altered by a simultaneous injection of either nonlabeled EPO-bi or control EPO, suggesting its nonspecific manner of distribution. Thus, it is evident that the clearance of EPO-bi differs from the rapid clearance of asialo-EPOL9-20 and EPO with sugar chains with greater than three N-acetyllactosamine repeating units,'' which are mediated by hepatic galactose-binding protein. 21 This accords with our previous findingI4 that the different in vivo activity of various EPO samples, including EPO-bi and control EPO, did not correlate with the extent of galactose exposure of sugar chains included in the samples.
According to the present knowledge on the difference in antennary structures of sugar chains between EPO-bi and control EPO, different metabolic behaviors of the two samples may be due to their physicochemical properties, such as the molecular weight of the sugar moiety and the negative charge depending on sialic acid content. EPO has a molecular weight of approximately 30 D, and this size seems to be critical for glomerular filtration of low-molecular-weight proteins.34 Thus, it is likely that EPO is filtrated by glomeruli more rapidly when its molecular size is diminished due to fewer branched antennary structures of sugar chains and a smaller content of sialic acid, as in the case of EPO-bi. The lower sialic acid content in EPO-bi also results in a reduced negative charge, and may cause a conformational change of the molecule that accelerates glomerular filtration. Another example of a recombinant glycoprotein that shows a rapid accumulation in the kidneys is a human granulocyte-macrophage colony-stimulating factor (GM-CSF).35 Approximately one third of GM-CSF, two potential sites of which are fully N-glycosylated, accumulated in the kidneys after 15 minutes of intravenous injection. The impaired glycosylation of GM-CSF by the site-directed mutagenesis of potential N-glycosylation sites resulted in a faster clearance from the circulation, but did not cause an increased accumulation in the kidneys. This observation complicates the explanation for the rapid distribution of EPO-bi to the kidneys. Further studies are needed to determine the precise mechanism. However, it is obvious that more rapid clearance of EPO-bi with fewer branched sugar chains is caused by renal handling. Evidence obtained in this study suggests that the wellbranched structure of the sugar chains of EPO may play an effective role in maintaining the higher plasma concentration of this hormone, which guarantees its delivery to target organs and higher expression of in vivo biologic activity.
